Corey E Bakalarski
Overview
Explore the profile of Corey E Bakalarski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
5090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hinkle T, Bakalarski C
J Proteome Res
. 2025 Feb;
PMID: 40019342
Selection and application of protein inference algorithms can have a significant impact on the data output from tandem mass spectrometry (MS/MS) experiments. However, this critical step is often taken for...
2.
Phung W, Bakalarski C, Hinkle T, Sandoval W, Marty M
Anal Chem
. 2023 Jul;
95(30):11491-11498.
PMID: 37478487
Recent advances in native mass spectrometry (MS) and denatured intact protein MS have made these techniques essential for biotherapeutic characterization. As MS analysis has increased in throughput and scale, new...
3.
Dejanovic B, Wu T, Tsai M, Graykowski D, Gandham V, Rose C, et al.
Nat Aging
. 2023 Apr;
2(9):837-850.
PMID: 37118504
Microglia and complement can mediate neurodegeneration in Alzheimer's disease (AD). By integrative multi-omics analysis, here we show that astrocytic and microglial proteins are increased in Tau synapse fractions with age...
4.
Davies C, Stowe I, Phung Q, Ho H, Bakalarski C, Gupta A, et al.
Proc Natl Acad Sci U S A
. 2021 Mar;
118(12).
PMID: 33723046
Inflammasomes sense a number of pathogen and host damage signals to initiate a signaling cascade that triggers inflammatory cell death, termed pyroptosis. The inflammatory caspases (1/4/5/11) are the key effectors...
5.
Goldstein L, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, et al.
Cell Rep
. 2016 Aug;
16(10):2605-2617.
PMID: 27568559
The Nrf2 pathway is frequently activated in human cancers through mutations in Nrf2 or its negative regulator KEAP1. Using a cell-line-derived gene signature for Nrf2 pathway activation, we found that...
6.
Bakalarski C, Gan Y, Wertz I, Lill J, Sandoval W
Nat Biotechnol
. 2016 Aug;
34(8):811-3.
PMID: 27504771
No abstract available.
7.
Bakalarski C, Kirkpatrick D
Mol Cell Proteomics
. 2016 Feb;
15(5):1489-97.
PMID: 26873251
High-throughput genomic and proteomic studies have generated near-comprehensive catalogs of biological constituents within many model systems. Nevertheless, static catalogs are often insufficient to fully describe the dynamic processes that drive...
8.
Varfolomeev E, Izrael-Tomasevic A, Yu K, Bustos D, Goncharov T, Belmont L, et al.
Biochem J
. 2014 Nov;
466(1):45-54.
PMID: 25423073
Evasion of cell death is one crucial capability acquired by tumour cells to ward-off anti-tumour therapies and represents a fundamental challenge to sustaining clinical efficacy for currently available agents. Inhibitor...
9.
Bingol B, Tea J, Phu L, Reichelt M, Bakalarski C, Song Q, et al.
Nature
. 2014 Jun;
510(7505):370-5.
PMID: 24896179
Cells maintain healthy mitochondria by degrading damaged mitochondria through mitophagy; defective mitophagy is linked to Parkinson's disease. Here we report that USP30, a deubiquitinase localized to mitochondria, antagonizes mitophagy driven...
10.
Kirkpatrick D, Bustos D, Dogan T, Chan J, Phu L, Young A, et al.
Proc Natl Acad Sci U S A
. 2013 Nov;
110(48):19426-31.
PMID: 24218548
Targeted therapeutics that block signal transduction through the RAS-RAF-MEK and PI3K-AKT-mTOR pathways offer significant promise for the treatment of human malignancies. Dual inhibition of MAP/ERK kinase (MEK) and phosphatidylinositol 3-kinase...